By Sabela Ojea

The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.

The federal regulator said Xacduro, which treats ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia, is hard to treat and poses a great threat to human health.

The FDA granted approval of Xacduro, administered by intravenous infusion, to Entasis Therapeutics, acquired by the pharma company Innoviva last year.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

May 23, 2023 18:55 ET (22:55 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Innoviva (NASDAQ:INVA)
過去 株価チャート
から 4 2024 まで 5 2024 Innovivaのチャートをもっと見るにはこちらをクリック
Innoviva (NASDAQ:INVA)
過去 株価チャート
から 5 2023 まで 5 2024 Innovivaのチャートをもっと見るにはこちらをクリック